Roger E. Susi, Founder, CEO, President, and Chairman of Iradimed Company (IRMD 1.15%), reported the oblique sale of seven,500 stocks of commonplace inventory over a couple of transactions on Might 18 and Might 19, 2026, for a complete worth of roughly $657,000 in line with the SEC Shape 4 submitting.
Transaction abstract
| Metric | Worth |
|---|---|
| Stocks bought (oblique) | 7,500 |
| Transaction worth | ~$657,000 |
| Submit-transaction stocks (oblique) | 4,397,950 |
Transaction worth in line with SEC Shape 4 weighted moderate acquire value ($87.64).
Key questions
- How does the dimensions of this sale examine to Roger E. Susi’s ancient transaction cadence?
With a mean of 21.6 trades in line with yr and conventional promote tranches starting from 5,000–10,000 stocks, this 7,500-share block is in keeping with the trend established since Might 2023, reflecting each ancient cadence and the declining to be had capability. - What portion of Susi’s possession used to be suffering from this transaction?
The sale of seven,500 stocks represented 0.17% of Susi’s oblique holdings on the time, leaving him with 4,397,950 stocks held by means of believe entities. - What’s the present context for Iradimed stocks following this transaction?
As of Might 22, 2026, stocks closed at $92.10, representing a one-year general go back of 82.77% as of Might 23, 2026, with the insider’s gross sales happening amid powerful percentage value appreciation and ongoing programmatic disposition of holdings.
Corporate evaluate
| Metric | Worth |
|---|---|
| Income (TTM) | $86.28 million |
| Web source of revenue (TTM) | $23.61 million |
| Dividend yield | 0.87% |
| 1-year value exchange | 82.77% |
* 1-year efficiency calculated the use of Might nineteenth, 2026 because the reference date.
Corporate snapshot
- Iradimed develops and markets MRI-compatible scientific units, together with intravenous infusion pump methods, affected person tracking methods, and comparable equipment.
- It generates income thru direct gross sales and distribution of proprietary {hardware} and consumables to healthcare suppliers.
- The corporate serves hospitals, acute care amenities, and outpatient imaging facilities as number one shoppers.
Iradimed Company operates at scale throughout the scientific software sector, focusing on MRI-compatible apparatus for essential care environments. The corporate leverages a centered product portfolio and direct gross sales method to deal with the original wishes of healthcare suppliers appearing MRI procedures.
Its aggressive edge is rooted in regulatory experience, product reliability, and established buyer relationships within the imaging and acute care markets.
What this transaction manner for buyers
The sale of Iradimed stocks on Might 18 and Might 19 by way of its founder and CEO isn’t a pink flag for buyers. The transaction used to be applied as a part of a Rule 10b5-1 buying and selling plan Roger Susi followed in November of 2025. Such plans are continuously applied by way of corporate executives to steer clear of accusations of constructing trades in line with insider data.
Additionally, Susi retained over 4 million stocks after the transaction, indicating that he maintains a large stake within the corporate. His sale got here at a time when Iradimed inventory used to be smartly above its 52-week low of $51.26 reached in 2025, however under the top of $107.90 accomplished in February of 2026.
The inventory value has risen due to Iradimed’s cast industry efficiency. The corporate reported 13% year-over-year income enlargement to $22 million within the first quarter. This helped it praise shareholders with a 22% year-over-year leap in Q1 diluted profits in line with percentage to $0.45.
Susi has carried out a very good task operating Iradimed, as its monetary efficiency demonstrates. It is sensible that he promote a few of his considerable holdings after serving to the industry carry out smartly.
Robert Izquierdo has no place in any of the shares discussed. The Motley Idiot has positions in and recommends Iradimed Company. The Motley Idiot has a disclosure coverage.
